DE69922804D1 - Verwendung von polymeren der hyaluronsäure zur mukosalen freigabe von impfstoffen und adjuvantien - Google Patents

Verwendung von polymeren der hyaluronsäure zur mukosalen freigabe von impfstoffen und adjuvantien

Info

Publication number
DE69922804D1
DE69922804D1 DE69922804T DE69922804T DE69922804D1 DE 69922804 D1 DE69922804 D1 DE 69922804D1 DE 69922804 T DE69922804 T DE 69922804T DE 69922804 T DE69922804 T DE 69922804T DE 69922804 D1 DE69922804 D1 DE 69922804D1
Authority
DE
Germany
Prior art keywords
hyaluronic acid
adjuvanties
vaccines
polymers
mucosal release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69922804T
Other languages
English (en)
Other versions
DE69922804T2 (de
Inventor
Derek O'hagan
Alessandra Pavesio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fidia Farmaceutici SpA
Novartis Vaccines and Diagnostics Inc
Original Assignee
Fidia Advanced Biopolymers SRL
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Advanced Biopolymers SRL, Chiron Corp filed Critical Fidia Advanced Biopolymers SRL
Application granted granted Critical
Publication of DE69922804D1 publication Critical patent/DE69922804D1/de
Publication of DE69922804T2 publication Critical patent/DE69922804T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DE69922804T 1998-06-01 1999-05-28 Verwendung von polymeren der hyaluronsäure zur mukosalen freigabe von impfstoffen und adjuvantien Expired - Lifetime DE69922804T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8759698P 1998-06-01 1998-06-01
US87596P 1998-06-01
PCT/US1999/012105 WO1999062546A1 (en) 1998-06-01 1999-05-28 Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants

Publications (2)

Publication Number Publication Date
DE69922804D1 true DE69922804D1 (de) 2005-01-27
DE69922804T2 DE69922804T2 (de) 2005-12-15

Family

ID=22206133

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69922804T Expired - Lifetime DE69922804T2 (de) 1998-06-01 1999-05-28 Verwendung von polymeren der hyaluronsäure zur mukosalen freigabe von impfstoffen und adjuvantien

Country Status (8)

Country Link
EP (1) EP1082135B1 (de)
JP (2) JP4610735B2 (de)
AT (1) ATE285250T1 (de)
AU (1) AU755465C (de)
CA (1) CA2332455C (de)
DE (1) DE69922804T2 (de)
ES (1) ES2235489T3 (de)
WO (1) WO1999062546A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002239697A1 (en) * 2000-10-24 2002-06-03 Clear Solutions Biotech, Inc. Sodium hyaluronate microspheres
DE10064219B9 (de) 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
US20020192205A1 (en) * 2001-05-11 2002-12-19 Francis Michon Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group A and group C streptococci
US7238338B1 (en) 2001-06-22 2007-07-03 Triumf System and method for the large scale labeling of compounds with radiohalogens
FR2847818B1 (fr) * 2002-11-28 2008-04-04 Agro Ind Rech S Et Dev Ard Composition pharmaceutique a base d'acide hyaluronique
WO2007047749A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics Inc. Mucosal and systemic immunizations with alphavirus replicon particles
CN104474543A (zh) * 2005-11-01 2015-04-01 诺华疫苗和诊断有限两合公司 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗
JP2009209086A (ja) * 2008-03-04 2009-09-17 Masami Moriyama 粘膜投与型ワクチン
JP2011057605A (ja) * 2009-09-09 2011-03-24 Masami Moriyama 粘膜投与型ワクチン

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
IT1247472B (it) * 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
JP3109886B2 (ja) * 1991-12-13 2000-11-20 デンカ生研株式会社 経鼻接種用ワクチン
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant

Also Published As

Publication number Publication date
ES2235489T3 (es) 2005-07-01
AU755465B2 (en) 2002-12-12
WO1999062546A1 (en) 1999-12-09
ATE285250T1 (de) 2005-01-15
AU4410699A (en) 1999-12-20
JP2010163432A (ja) 2010-07-29
CA2332455C (en) 2012-08-14
JP4610735B2 (ja) 2011-01-12
EP1082135B1 (de) 2004-12-22
CA2332455A1 (en) 1999-12-09
DE69922804T2 (de) 2005-12-15
EP1082135A1 (de) 2001-03-14
AU755465C (en) 2004-01-29
JP2002516876A (ja) 2002-06-11

Similar Documents

Publication Publication Date Title
AU4673099A (en) Use of bioadhesives and adjuvants for the mucosal delivery of antigens
MXPA01011047A (es) Secuencias genomicas de neisseria y metodos para su uso.
FR20C1016I1 (de)
NO20015073L (no) Vaksiner
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
MXPA01003557A (es) Secuencias genomicas de neisseria y metodos para su uso.
WO2001034801A3 (en) Recombinant gelatin in vaccines
MY129263A (en) Vaccine composition
PT851927E (pt) Compostos para imunoterapia e diagnostico de tuberculose
CY1114643T1 (el) Νεοπλασματικες κυτταρικες σειρες nm-f9 (dsm acc2606) και nm-d4 (dsm acc2605), χρησεις αυτων
DK1326633T3 (da) Sammensætning omfattende immunogene mikropartikler
ATE254474T1 (de) Impfstoffzusammensetzung gegen herpes simplex virus und methoden zur verwendung
GB2386072A (en) Novel vaccine
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
DE69922804D1 (de) Verwendung von polymeren der hyaluronsäure zur mukosalen freigabe von impfstoffen und adjuvantien
WO2002024739A3 (en) Spas-1 cancer antigen
BR9704879A (pt) Composição de vacina e uso de um vírus cav vivo
DE59101580D1 (de) Trägergebundene rekombinante proteine, verfahren zur herstellung und verwendung als immunogene und vakzine.
ATE503491T1 (de) Verbesserte anthraximpfstoffe und abgabeverfahren
PT1272652E (pt) Virus de herpes para a modulacao imunitaria
NO20020615D0 (no) Vaksine
WO2004098529A3 (en) Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules
DK1159426T3 (da) Kloning og udtryk af Haemophilus somnus transferrin-bindende proteiner
ATE350058T1 (de) Sich gegenseitig schützende herpesviruszusammensetzung und verfahren zur deren herstellung und verwendung
DK1221969T3 (da) Aktivering af antigen-specifikke T-celler med virus/antigen-behandlede dendritiske celler

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: CHIRON CORP. (N.D.GES.D. STAATES DELAWARE), EMERYV

Owner name: FIDIA FARMACEUTICI S.P.A., ABANO TERME, PADUA/PADO

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: FIDIA FARMACEUTICI S.P.A., ABANO TERME, PADUA/, IT

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US